Answers are grounded in this paper and cite their sources.
Histone deacetylase 2 (HDAC2) may contribute to epigenetic dysregulation in esophageal squamous cell carcinoma (ESCC) by silencing tumor suppressor genes, yet isoform-specific therapeutic targeting remains underexplored. Here, we show that romidepsin, an FDA-approved class I HDAC inhibitor, preferentially inhibits HDAC2-associated deacetylation in ESCC cells. We identified romidepsin as a potent inhibitor of ESCC cell viability, through phenotypic screening of 773 epigenetic compounds across differentiation-stage-defined ESCC models. Multi-omics analyses (SILAC proteomics, CUT&Tag chromatin mapping, and RNA-seq) further revealed histone H3K14ac enrichment at promoters of p53 pathway targets, including CDKN1A/p21, which exhibited transcriptional reactivation. Similar to HDAC2 knockout, romidepsin suppressed ESCC proliferation, migration, and clonogenicity. Mechanistically, HDAC2 inhibition reverses epigenetic silencing of p21 and restores tumor-suppressive chromatin states. Together, these results identify the HDAC2–H3K14ac axis as a therapeutic vulnerability in ESCC and provide preclinical support for romidepsin-based epigenetic intervention.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: